{"id":966611,"date":"2026-05-26T06:05:31","date_gmt":"2026-05-26T10:05:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors\/"},"modified":"2026-05-26T06:05:31","modified_gmt":"2026-05-26T10:05:31","slug":"kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-reports-strong-clinical-activity-and-safety-with-darlifarnib-adagrasib-in-kras-g12c-mutated-solid-tumors\/","title":{"rendered":"Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors"},"content":{"rendered":"
\n

\n \u2013 Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients \u2013<\/em>\n <\/p>\n

\n \u2013 ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-na\u00efve CRC patients \u2013<\/em>\n <\/p>\n

\n \u2013 Results reinforce darlifarnib\u2019s potential as a precision combination agent across targeted therapies \u2013<\/em>\n <\/p>\n

\n \u2013 Clear clinical activity in KRASi-experienced patients and manageable safety profile \u2013<\/em>\n <\/p>\n

\n \u2013 Virtual investor event on June 3, 2026, at\u00a012:15 p.m. PT\u00a0\/\u00a03:15 p.m. ET\u00a0\u2013<\/em>\n <\/p>\n

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc.\u00a0(Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily pretreated patients with KRAS<\/em> G12C-mutated advanced solid tumors. The results will be presented at the 2026 American Society of Clinical Oncology\u00a0(ASCO) Annual Meeting on\u00a0May 30, 2026.<\/p>\n

The combination of darlifarnib plus adagrasib demonstrated meaningful antitumor activity in heavily pretreated pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) patients with prior KRAS inhibitor (KRASi) exposure, as well as KRASi-na\u00efve colorectal cancer (CRC) patients. These data provide clinical proof-of-mechanism for Kura\u2019s FTI platform as a precision combination that blocks RHEB-dependent mTORC1 signaling, a key resistance pathway shared across multiple targeted therapy classes.<\/p>\n

\u201cThese results are very encouraging for patients and represent a major milestone for the FTI field,\u201d said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. \u201cDarlifarnib delivered robust tumor shrinkage and high objective response rates across KRAS<\/em> G12C-mutated PDAC, NSCLC and CRC. These data compare favorably to adagrasib monotherapy benchmarks and demonstrate consistent, meaningful clinical activity in three difficult-to-treat tumor types. This marks \u201cthree-for-three\u201d for targeting the mTORC1-RHEB pathway using an FTI approach to overcome resistance to targeted therapies, building on prior positive combinations with VEGFR tyrosine kinase inhibitors and PI3K\u03b1 inhibitors, and now KRAS inhibitors. With compelling clinical activity across multiple tumor types and a manageable safety profile, darlifarnib is well-positioned as a preferred combination partner for KRAS inhibitors and other precision therapies.\u201d<\/p>\n

\u201cRAS inhibitors have raised the bar in the treatment of KRAS<\/em>-mutated cancers, but resistance remains a major limitation of current therapies,\u201d said David S. Hong, M.D., Deputy Chair of the Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. \u201cThis approach targeting a key downstream resistance node is exciting, and the early activity and tolerability of darlifarnib plus adagrasib support further development of this combination to deepen and extend responses.\u201d<\/p>\n

\n Key Highlights (Phase 1a, N=30; 26 response evaluable): <\/strong>\n <\/p>\n